Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: SMARCB1 (INI1)-deficient intrathoracic neoplasms are rare and highly malignant. We report a case of a patient with this tumor who was initially diagnosed with non-small cell lung cancer and whose disease rapidly progressed to death despite chemotherapy.

Case Presentation: A man in his 60s was diagnosed with a mass exceeding 10 cm in the lower lobe of the right lung and a right pleural effusion on the first examination. Transbronchial biopsy of the primary lesion revealed a tumor with rhabdoid features, which was diagnosed as an undifferentiated malignant neoplasm. Clinically, the patient was diagnosed with non-small cell lung cancer and was treated with carboplatin, nab-paclitaxel, durvalumab, and tremelimumab. However, at the end of the second course, there was rapid disease progression. Based on a pathological review, the tumor was considered an SMARCB1-deficient intrathoracic neoplasm. Although we considered further treatment, his general condition deteriorated, and he died about 2 months after his first visit.

Conclusion: This disease is rare, and we believe that it is necessary to disseminate the concept of this disease and accumulate knowledge to establish a treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913462PMC
http://dx.doi.org/10.1159/000544167DOI Listing

Publication Analysis

Top Keywords

non-small cell
12
cell lung
12
lung cancer
12
smarcb1 ini1-deficient
8
ini1-deficient intrathoracic
8
intrathoracic neoplasm
8
rapidly progressed
8
diagnosed non-small
8
case smarcb1
4
neoplasm respond
4

Similar Publications

Purpose: Frailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.

Methods: This retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI).

View Article and Find Full Text PDF

Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.

View Article and Find Full Text PDF

Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.

View Article and Find Full Text PDF

Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.

Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.

View Article and Find Full Text PDF